SEMDA 2013 Conference Breaks Prior Records
Published: Mar 01, 2013
ATLANTA, GA--(Marketwire - February 28, 2013) -
The SEMDA 2013 Conference also had a record number of participating companies, with 20 companies highlighting their technology and devices before a crowd that included an estimated 60 seed, angel and venture capital investors, private equity and large corporations seeking new acquisitions. This was the first year that medical device data system (MDDS) companies have been included in the SEMDA Conference.
"The SEMDA Conference has grown from a local gathering to a Southeastern-focused event that draws attendance from across the country," said Robert L. Crutchfield, who assumed the role of SEMDA President for 2013-2014 at the Conference. Crutchfield is a Partner at Harbert Venture Partners, with offices in Birmingham, AL and Richmond, VA.
"An event of this scope and excellence requires countless hours of work from a large team of volunteers. We were fortunate to have Arthur Spalding, founder of TAMM Net, Inc., as the Chair of the conference this year," Crutchfield continued. "He has set a high bar, but his focus on building a strong structure to support next year's team gives us a head start on 2014."
Angela Sinton, Senior Partner at Medical Device Marketing, LLC, served as Conference co-chair and also chaired the presenting company committee. Sinton was recognized with the Chairman's award for outstanding volunteer at the close of the Conference.
"The annual SEMDA Conference is an opportunity to bring together everyone involved with the medtech industry in the Southeast," said Charlie Harrison, the outgoing SEMDA President. "It is always exciting to see the connections that are made at the Conference, and then to find out that those connections led to mutual opportunities and success."
Recognized as the premier gathering for the Southeast medical device industry, the Conference included presentations to investors along with programs, 1:1 partnering and networking opportunities. Program speakers and panelists included executives from multinational medical device companies, the FDA and acclaimed specialists.